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Gordon J Lithgow1*, Janet M Lord2* and James L Kirkland3*At the beginning of the 20th century the names of deadly
childhood diseases were whispered in fear. Everyone
knew a family visited by the shadow of tuberculosis,
rickets, polio or smallpox. Chickenpox and rubella
brought their own forms of misery. Each disease pre-
sented in different ways, affected different organs and
had distinct prognoses. Many of us will remember the
endless cycles of bake sales and charity runs aimed at
raising funds to buy iron lungs for local children badly
damaged by polio, and the strings of sanatoriums built
for the isolation and treatment of tuberculosis. At the
beginning of the 21st century, young parents are scarcely
aware of the names of these conditions, never mind stress
over their children contracting them. What happened?
The germ theory of infectious disease provided the causal
framework for the development of Erlich’s magic bullets,
Fleming’s antibiotics and Salk’s vaccine. Society didn’t
need more iron lungs or sanatoriums; it needed preven-
tions and cures and it got them through investment in mi-
crobial, immunological and pharmaceutical research.
At the beginning of the 21st century, the names of diffe-
rent deadly diseases are now whispered. Every family is
visited by cancer, Alzheimer’s, Parkinson’s, heart disease,
type 2 diabetes or stroke. Other conditions such as arthritis,
macular degeneration and generalized frailty bring misery
to millions of older adults and their families. Each disease
presents itself in different ways, affects different organs and
has distinct prognoses. The bake sales and charity runs are
still with us; this time it’s not the children they intend to
benefit. Our seniors are now the target and there is an ur-
gency to combat these conditions as we are a rapidly aging
population. Life expectancy is increasing at approximately
two years per decade, with the increase in our elders
greatest in the oldest old, the over 85 years group. As a
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reproduction in any medium, provided the ormajor age-related conditions, the impact of ill health in
this age group is significant and growing. Unlike child-
hood infectious diseases, the chronic diseases of late life
are not generally recognized to share a common cause.
Their diversity challenges the notion that one or two
therapeutic principles could be discovered. But what if
there was a common cause to diseases such as cancer and
Alzheimer’s? What if “broad spectrum” treatments could
be developed? The impact on human suffering would cer-
tainly rival the arrival of antibiotics and vaccines and the
economic impact would probably be even greater.
The launch of this new journal originates in a belief
held by an increasing number of biomedical researchers.
The belief is that the chronic diseases of late life do in-
deed have a single or at least a limited number of causes
that can be discovered by studying the mechanisms of
normal aging. There is increasing evidence that mecha-
nisms that determine the rate of aging are intimately
related to the early events in disease pathology. If this is
true, then the notion that a small number of therapeutic
approaches, including both lifestyle and pharmacological
interventions, might be efficacious against a constella-
tion of age-related conditions. Longevity & Healthspan is
intended to serve as a venue for this emerging science.
Aging and its connection to disease is perhaps the most
complex biological problem imaginable and many very
difficult challenges lie ahead. Critically, the progress
made in understanding factors that determine the rate
of aging in animal models has not yet been translated
into clinical research. We intend Longevity & Healthspan
to capture the translational science that should emerge
over the next few years.
This journal is being launched at a time of great excite-
ment and optimism in the aging field. The optimism comes
from decades of observing healthy lifespan extension resul-
ting from caloric restriction of laboratory rodents. It comes
from the ease with which aging can be slowed in inverte-
brates by genetic and small molecule interventions. It
comes from the fine example of successful aging in cente-
narians. But mostly, the optimism comes from a new gene-
ration of scientists who have observed the plasticity of
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scientists is comfortable working in interdisciplinary teams,
an increasingly important skill. Understanding how aging is
mechanistically related to disease will require research at
the interface of areas of expertise, particularly between basic
and clinical scientists.
Longevity & Healthspan aims to serve an important role
at the interface of basic and clinical aging science. The
editorial board is formed from prominent researchers
from across a spectrum of basic scientists and clinicians.
We expect to publish research from a wide range of
disciplines, from model organisms to human clinical
studies. We will solicit meeting reports and reviews tar-
geted at emerging areas of interest particularly at the
interface of aging and disease. Following peer review, all
accepted articles will be free to access online imme-
diately upon publication and in perpetuity, and authors
will retain copyright.
We are delighted that BioMed Central has recognized
the need and opportunities for a new journal at this time
in the development of the aging field and look forward
to publishing exciting discoveries in the coming years.
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